Fecal microbiota transplantation for the treatment of Clostridium difficile infection
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Clostridium difficile, a major cause of healthcare‐associated diarrhea due to perturbation of the normal gastrointestinal microbiome, is responsible for significant morbidity, mortality, and healthcare expenditures. The incidence and severity of C difficile infection (CDI) is increasing, and recurrent disease is common. Recurrent infection can be difficult to manage with conventional antibiotic therapy. Fecal microbiota transplantation (FMT), which involves instillation of stool from a healthy donor into the gastrointestinal tract of the patient, restores the gut microbiome to a healthy state. FMT has emerged as a promising new treatment for CDI. There are limited data on FMT for treatment of primary CDI, but FMT appears safe and effective for recurrent CDI. The safety and efficacy of FMT in patients with severe primary or severe recurrent CDI has not been established. Patients with inflammatory bowel disease (IBD) who undergo FMT for CDI may be at increased risk of IBD flare, and caution should be exercised with use of FMT in that population. The long‐term safety of FMT is unknown; thus, rigorously conducted prospective studies are needed. Journal of Hospital Medicine 2016;11:56–61. © 2015 Society of Hospital Medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiota in health and disease
Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010) · Physiological Reviews · doi:10.1152/physrev.00045.2009 · Cited by 4,182 · cited 1×
“associated with colon cancer, diabetes, obesity, and atopic disorders.(56) The role of FMT in contributing to”
BackgroundDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“The first randomized, controlled clinical trial (RCT) of FMT for recurrent CDI was reported in 2013.(39) Three treatment groups were compared: vancomycin for 5 days followed by FMT (n 5 16), vancomycin alone for 14 days (n 5 13), or vancomycin for 14 days with bowel lavage (n 5 13).”
MethodBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641 · cited 1×
“billion in excess healthcare costs each year in the United States,(11) and that much of the additional cost and morbidity of CDI is due to recurrence, with around 83,000 cases per year.(6) The human gut microbiota, which is a diverse ecosystem consisting of thousands of bacterial species,(12) protects against invasive…”
BackgroundAntibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
Bartlett, J. G., Chang, T. W., Gurwith, M., Gorbach, S. L., & Onderdonk, A. B. (1978) · New England Journal of Medicine · doi:10.1056/nejm197803092981003 · Cited by 1,374
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Treating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
Theriot, C. M., Koenigsknecht, M. J., Carlson, P. E., Hatton, G. E., Nelson, A. M., Li, B., Huffnagle, G. B., Z. Li, J., & Young, V. B. (2014) · Nature Communications · doi:10.1038/ncomms4114 · Cited by 974
Rossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921 · cited 1×
“(without CDI) treated via FMT did not show any significant adverse events.(55) FMT side effects may vary”
MethodKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Brandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672 · cited 1×
“In the only study to capture long-term outcomes after FMT, 77 patients were followed for 3 to 68 months (mean 17 months).(57) New conditions such as ovarian cancer, myocardial infarction, autoimmune”
Background
Cited by
Postler, T. S., & Ghosh, S. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.05.008 · Cited by 876
“A technique that dates back to the 4th century CE, FMTs have most recently been used as experimental treatments for recurrent infection with Clostridium difficile, with promising results (Rao and Safdar, 2016; van Nood et al., 2013; Zhang et al., 2012).”
MethodCammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319548 · Cited by 506
Gut microbiota: A player in aging and a target for anti-aging intervention
Vaiserman, A. M., Koliada, A. K., & Marotta, F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.01.001 · Cited by 465
Diagnosis and Treatment of Clostridium difficile in Adults: A Systematic Review
Bagdasarian, N., Rao, K., & Malani, P. N. (2015) · JAMA · doi:10.1001/jama.2014.17103 · Cited by 451
Self-citationGut microbiota changes in the extreme decades of human life: a focus on centenarians
Santoro, A., Ostan, R., Candela, M., Biagi, E., Brigidi, P., Capri, M., & Franceschi, C. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2674-y · Cited by 250
“Initially, bacteriotherapy was developed as an effective method of treating Clostridium difficile infection, which is a major cause of healthcare-associated diarrhea through perturbation of the normal GM [150].”
MethodEl Hage, R., Hernandez-Sanabria, E., & Van de Wiele, T. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01889 · Cited by 185
“However, FMT can resolve both CDI and rCDI (Bakken, 2009), with a success rate of 90% when further antibiotic treatments fail (Youngster et al., 2014; Rao and Safdar, 2015).”
BackgroundApplications of gut microbiota in patients with hematopoietic stem-cell transplantation
Yu, J., Sun, H., Cao, W., Han, L., Song, Y., Wan, D., & Jiang, Z. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00194-y · Cited by 25
Metadata
- Authors
- Rao, K., & Safdar, N.
- Venue
- Journal of Hospital Medicine
- Publisher
- Wiley
- Published
- 2015-09-07
- Volume
- 11
- Issue
- 1
- Pages
- 56-61
- ISSN
- 1553-5592 (ISSN-L)
- 1553-5606
- OpenAlex
- W1900902556
- Cited by
- 70
- References
- 24
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.